Joyce M. Slingerland
University of Miami
131 Papers
1.9K Citations
Joyce M. Slingerland is an academic researcher from University of Miami. The author has contributed to research in topics: Cyclin-dependent kinase & Cancer. The author has an hindex of 62, co-authored 125 publications. Previous affiliations of Joyce M. Slingerland include McGill University & Ontario Institute for Cancer Research.
Chat about Author
Papers
Cytoplasmic p27 promotes epithelial–mesenchymal transition and tumor metastasis via STAT3-mediated Twist1 upregulation
Dekuang Zhao,Alexandra H. Besser,Seth A. Wander,Jun Sun,Wen Zhou,Bin Wang,Tan A. Ince,Michael A. Durante,Wei Guo,Gordon B. Mills,Dan Theodorescu,Joyce M. Slingerland +11 more
TL;DR: An oncogenic feedforward loop in which p27pT157pT198 binds Janus kinase 2 (JAK2) promoting STAT3 (signal transducer and activator of transcription 3) recruitment and activation is described.
Cytokines, Obesity, and Cancer: New Insights on Mechanisms Linking Obesity to Cancer Risk and Progression
TL;DR: Enhanced cytokine production in obese adipose tissue may serve both as a chemoattractant for invading cancers and to augment their malignant potential, suggesting that the current obesity epidemic will presage a significant increase in cancer incidence, morbidity, and mortality in the next few decades.
Long-Range Activation of GREB1 by Estrogen Receptor via Three Distal Consensus Estrogen-Responsive Elements in Breast Cancer Cells
TL;DR: Data suggest that estrogen-stimulated GREB1 transcription may involve coordinated ER binding to all three distal consensus ERE motifs, suggesting that long-range activation by ER acting at multiple EREs may be more common than previously appreciated.
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells
Fiona Simpkins,Fiona Simpkins,Kibeom Jang,Hyunho Yoon,Karina E. Hew,Minsoon Kim,Diana J. Azzam,Jun Sun,Dekuang Zhao,Tan A. Ince,Wenbin Liu,Wei Guo,Zhi Wei,Gao Zhang,Gordon B. Mills,Joyce M. Slingerland +15 more
TL;DR: Selumetinib added to saracatinib overcomes EGFR/HER2/ERBB2–mediated bypass activation of MEK/MAPK observed with saracasinib alone and targets tumor-initiating ovarian cancer populations, supporting further evaluation of combined Src–MEK inhibition in clinical trials.
p27 Deregulation in Breast Cancer: Prognostic Significance and Implications for Therapy
TL;DR: The prognostic significance of p27 in human breast cancer and the possible therapeutic implications of these findings will also be reviewed.